* VENCLEXTA® (venetoclax) plus obinutuzumab is the first chemotherapy-free,
fixed-duration combination regimen approved by Health Canada for patients
with previously untreated chronic lymphocytic leukemia (CLL).
* Approval is based on data from the Phase 3 CLL14 trial, which showed that
patients treated with obinutuzumab plus one year of treatment with
VENCLEXTA had clinically meaningful and statistically significant
progression-free survival (PFS) and higher rates of undetectable minimal
residual disease compared to patients receiving a standard of care
chemoimmunotherapy regimen of obinutuzumab and chlorambucil
bloomberg.com/press-release...
This is an unlocked post: healthunlocked.com/cllsuppo...
Neil